The House proudly passed Substitute House Bill 6771 establishing a legal requirement for health insurance policies to cover biomarker testing, a type of medical testing that analyzes biological samples—such as tissue or blood—to detect molecular signs (biomarkers) of health conditions or treatment responses.
Key points of the bill include:
-
Mandatory Coverage: Health insurance must cover biomarker tests when used for diagnosing, treating, managing, or monitoring diseases.
-
Evidence-Based Requirement: Coverage is contingent upon the test having demonstrated clinical utility, meaning it must be supported by:
-
FDA approval or clearance,
-
Medicare coverage determinations, or
-
Clinical practice guidelines recognized by the medical community
The bill aims to expand access to potentially life-saving or life-improving tests, especially in personalized or precision medicine, while also ensuring that only scientifically validated tests are covered.
|